SK Bioscience's shingles vaccine obtains product approval from Malaysia

SK Bioscience Co. said on Monday that its shingles vaccine Sky Zoster has been given approval by Malaysia's National Pharmaceutical Regulatory Agency.

Sky Zoster is a live attenuated vaccine developed by SK Bioscience with its proprietary technology and was approved by the Korean Ministry of Food and Drug Safety in 2017.

It is the second time that Sky Zoster has been approved overseas after Thailand in May 2020.

SK Bioscience will apply for pre-qualification (PQ) for Sky Zoster with the World Health Organization this year.

PQ is a system by which the WHO evaluates the safety and effectiveness before supplying vaccines and medicines to developing countries.

“We will expand the products based on our technology as much as possible given our company's status in the world market has been upgraded after consignment production and self-development of COVID vaccines," said Ahn Jae-yong, CEO of SK Bioscience. 

Write to Jung-Eun Kim at likesmile@hankyung.com